Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

http://www.wikidata.org/entity/Q35102656

about

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In Vivo Efficacy in a Mouse Model of Tuberculosis Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam Bactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection model Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis A high-throughput cidality screen for Mycobacterium tuberculosis Unravelling the Secrets of Mycobacterial Cidality through the Lens of Antisense In silico evaluation and exploration of antibiotic tuberculosis treatment regimens A multi-scale approach to designing therapeutics for tuberculosis A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment Mycolic acids as diagnostic markers for tuberculosis case detection in humans and drug efficacy in mice Pipeline of drugs for related diseases: tuberculosis Repurposing clinically approved cephalosporins for tuberculosis therapy Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates Tuberculosis therapy for 2016 and beyond.Insights into the pharmacokinetic properties of antitubercular drugs.Recent advances in tuberculosis: New drugs and treatment regimens.Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.Understanding pharmacokinetics to improve tuberculosis treatment outcome.Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis.Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infection Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.PA-824 exhibits time-dependent activity in a murine model of tuberculosis.Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis.Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy

P2860

Q21144660-994BC18C-F2ED-400D-A2D5-D4CE1E2DA5B3 Q27324299-F4799C5E-61CD-462E-B4DE-8C900F4148D3 Q27680342-DBA4A13B-EBC1-445B-BE3D-39F0C3D6A3F1 Q28477456-2FB10EF9-E2C3-4521-B8FE-9576EA54CC0D Q28478890-70548CA0-AC53-4DF8-8DC4-39E2CA8CD5B1 Q28487137-D5284473-26C7-4B2B-B923-69B67FDCD369 Q28538952-D13677F8-40D5-4000-8461-DCE0E985B25C Q28539383-E36BFF00-DC9F-4860-A142-0671D9E9BC73 Q28542435-9C47F44C-F4C1-4788-91AB-C76082D8D9D6 Q28543482-06C72CA1-DE85-4E27-A812-40CE91DF3199 Q28551800-C149DA79-2DA4-4453-946A-D8E1D54BFCE3 Q28607283-4D9BAA73-F62E-44DF-8593-10E79D3F3B6B Q28647309-686B36A4-A9EC-44F3-9E0E-06D4BC9B1459 Q28649754-0518F4FE-A42C-43F2-A50B-4A5F0FE2FC09 Q28728356-B9E78828-872A-43D2-B0BE-5F326F58DF86 Q28818217-241A4C30-8944-4192-886E-A77717292F93 Q28828720-37589ED0-1AD9-43E6-916C-27CEEFC6975E Q29618010-B46A2348-E3AB-44DE-8618-F6BE6D7FD453 Q30248788-D3777A31-A012-4F86-AA74-FEFD5927982E Q30251497-02CE36EA-A17C-4D50-A8EB-404D76D2E6A2 Q30360811-2F423504-27BA-42B5-9929-3C683E454130 Q30383012-557CCA47-4084-4450-87D5-1D7C6C6C415A Q30411703-57956EEB-52C5-4BEE-B223-D81C22C754BE Q30498213-33996184-A76D-481E-B6A7-449D91778446 Q33282527-6342FE3F-C4B2-43A0-90E1-D8E409B2286B Q33291134-6E1B9528-17CB-4208-8FE7-35B0F2C75DD7 Q33621748-B659D54D-6A0B-4A52-89EA-1578F883061F Q33622963-5CA4C677-15F4-4326-A764-63E8904BA5CE Q33735589-CCC54532-99E0-43B4-85F4-25A7CE4AB94B Q33798061-58EC9176-EA2F-42CE-A38B-D0226306E134 Q34108761-5FDED73D-BA73-46B9-BF47-38F8CCB0978A Q34150929-BC648569-628B-4022-AE7F-1BC12D46C10F Q34483632-DDCCA3F5-65FC-4213-8C23-70C54A0C2487 Q34510604-A9656400-6E31-4865-8098-7DC073448869 Q34510679-D578CCB5-78BC-4192-86CE-6B8FF77D0580 Q34561741-133CEBF6-9E87-44C5-A34D-096C7146DFE2 Q34591451-B26C385D-DD62-4FEA-B419-522ABAB77DFE Q34597564-BC7E6A21-E00C-422B-B33C-0F60EE591B42 Q34729493-090B6918-8087-410E-8257-5E3F4ACFF509 Q34778531-29D65224-DF13-4EBF-A7BB-48C2F3242F96

P2860

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

http://www.wikidata.org/entity/Q35102656

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Pharmacokinetics-pharmacodynam ...... fection model of tuberculosis.

@ast

Pharmacokinetics-pharmacodynam ...... fection model of tuberculosis.

@en

type

label

Pharmacokinetics-pharmacodynam ...... fection model of tuberculosis.

@ast

Pharmacokinetics-pharmacodynam ...... fection model of tuberculosis.

@en

prefLabel

Pharmacokinetics-pharmacodynam ...... fection model of tuberculosis.

@ast

Pharmacokinetics-pharmacodynam ...... fection model of tuberculosis.

@en

P1433

Q35102656-991DBE67-BD4A-471D-8254-28F1FE43A257

P1476

Q35102656-57348074-81A9-4B7D-B57F-D7764297510E

P2093

Q35102656-26A7E5EA-D571-46E8-A4A3-6911CF680C84

Q35102656-334AA97D-FC46-460D-B2D9-EA1EEE1CF362

Q35102656-61081272-509C-47B9-B453-FA30B3B9C224

Q35102656-6A61C6E1-CFF5-43B1-8FD3-A9D8D8A31B42

Q35102656-9DBC77E2-22FE-44A5-BEAF-563D456F2E35

Q35102656-9F6A4B64-0698-4749-83CA-5E18280B2F14

Q35102656-B0EC646E-9CEC-4FDA-9D63-4BD62DA5D74A

Q35102656-C205CFE9-8F0F-40CC-BF11-4D6E1BA10D6F

Q35102656-C63C11BB-A0D7-488F-ABD7-9503EA64F04B

Q35102656-CA75D222-CCEF-4798-B80C-6DB993ED5A7D

P2860

Q35102656-097F6D53-AB86-44F7-90D6-103BE7A861D5

Q35102656-0DF4543F-2AF4-49D2-9D12-73E5E90ECD38

Q35102656-10762106-C425-44FF-B4AB-CFD5CC80451A

Q35102656-15232F26-E80D-4B20-8E9F-90AA54C6C2FF

Q35102656-1F77D93B-31FA-4FA2-9027-34DBA44E461E

Q35102656-260E33A3-BFD7-4553-A31C-A7F43B533174

Q35102656-3CC83872-E8F6-43BE-BA6D-3ECFF8700B17

Q35102656-3E5F1FF4-7519-4AB5-842E-73BB89D2188B

Q35102656-48A0F092-D1D8-4C50-8B6F-B2B3B9DFBAAD

Q35102656-4E85E4E8-FB84-450A-A9D1-0B1B6A2FA840

P304

Q35102656-19BE7E34-6D23-4250-9005-60867F974DBD

P31

Q35102656-CB37146C-4981-4415-AA5F-4E5EF82D2407

P356

Q35102656-D8DBCBED-5E45-47C5-BC0B-450CD9FF6D7A

P407

Q35102656-55B4F45C-70BB-4052-9A40-1C9C40DDB7E6

P433

Q35102656-30D28822-29EA-46BE-BDE8-7662B7DEFE95

P478

Q35102656-BF6E2F6B-747D-4911-8D5F-78CFB1A281B1

P577

Q35102656-0620CFBE-DDA0-4958-B059-64CBAFACF1FF

P698

Q35102656-9B13C356-4A02-4AB6-89D2-47F7118426D2

P921

Q35102656-0DF4E706-6191-43CD-A96A-19530845A395

Q35102656-A106F1A0-BFD7-4EEB-9681-6F0530F68918

P932

Q35102656-2B32C378-F4A5-4394-99C6-588116736604

P356

AAC.47.7.2118-2124.2003

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics-pharmacodynam ...... fection model of tuberculosis.

@en

P2093

B L Suresh

http://www.w3.org/2001/XMLSchema#string

B N Mahesh

http://www.w3.org/2001/XMLSchema#string

E Kantharaj

http://www.w3.org/2001/XMLSchema#string

Parvinder Kaur

http://www.w3.org/2001/XMLSchema#string

R Jayashree

http://www.w3.org/2001/XMLSchema#string

R K Shandil

http://www.w3.org/2001/XMLSchema#string

Ramesh Jayaram

http://www.w3.org/2001/XMLSchema#string

Sheshagiri Gaonkar

http://www.w3.org/2001/XMLSchema#string

Sowmya Bharat

http://www.w3.org/2001/XMLSchema#string

V Balasubramanian

http://www.w3.org/2001/XMLSchema#string

P2860

Role of individual drugs in the chemotherapy of tuberculosis

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol

Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages

Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model

Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model

Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis

Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages

In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations

P304

2118-2124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.47.7.2118-2124.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12821456

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

161844

http://www.w3.org/2001/XMLSchema#string